- Brand names:
- Pharmaceutical Company:
- Condition/Indication: All adalimumab indications except juvenile idiopathic arthritis.Severe active rheumatoid arthritis.
- Meeting Date: November 2022
- Public Summary Document (PSD) November 2022 PBAC Meeting - (PDF 503KB)
- Public Summary Document (PSD) November 2022 PBAC Meeting - (Word 134KB)
Adalimumab upadacitinib – November 2022
Adalimumab: Injection 20 mg in 0.2 mL pre-filled syringe, Injection 40 mg in 0.4 mL pre-filled pen, Injection 40 mg in 0.4 mL pre-filled syringe, Injection 80 mg in 0.8 mL pre-filled pen, Injection 80 mg in 0.8 mL pre-filled syringe; Humira® and Upadacitinib: Tablet 15 mg; Rinvoq®
Last updated
17 March 2023
